{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:10:13Z","timestamp":1790921413242,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The mature T\/natural killer (NK) lymphoma\/leukemias represent 5\u201315% of all non-Hodgkin lymphoma. These diseases have a geographic variation, with more nodal disease in North America and Europe, including peripheral T cell lymphomas, unspecified, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma; and more extranodal disease in Asia due to Epstein-Barr virus\u2013related nasal NK\/T lymphoma and human T-cell leukemia virus (HTLV)-1\u2013associated adult T cell leukemia\/lymphoma. The prognosis in most peripheral T\/NK neoplasms is poor, with 5-year survival less than 30%. Progress has been slow due to the rarity of the diseases, geographic variation, relative chemoresistance, and lack of randomized trials. There is no consensus about optimal therapy in T\/NK neoplasms, and recommendations are based on anecdotal reports, small series, and phase II trials. In this review, topics include the question of CHOP as standard therapy, prognostic factors, disease-adapted therapy, novel approaches, monoclonal antibody therapy, and stem cell transplantation.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.331","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"331-337","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Therapy of Peripheral T\/NK Neoplasms"],"prefix":"10.1182","volume":"2006","author":[{"given":"John P.","family":"Greer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703413905500_R1","doi-asserted-by":"crossref","unstructured":"Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: Clinical features and prognostic factors of 92 cases defined by the revised European American Lymphoma Classification. Leuk Lymph. 2003;44:241\u2013249.","DOI":"10.1080\/1042819021000030054"},{"key":"2019111703413905500_R2","doi-asserted-by":"crossref","unstructured":"Savage KJ, Chanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467\u20131475.","DOI":"10.1093\/annonc\/mdh392"},{"key":"2019111703413905500_R3","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913\u20133921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"2019111703413905500_R4","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Blood. 1998;92:76\u201382."},{"key":"2019111703413905500_R5","doi-asserted-by":"crossref","unstructured":"Evens AM, Gartenshaus RB. Treatment of T-cell Non-Hodgkin\u2019s Lymphoma. Curr Treat Opt Oncol. 2004;5:289\u2013303.","DOI":"10.1007\/s11864-004-0020-8"},{"key":"2019111703413905500_R6","doi-asserted-by":"crossref","unstructured":"Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255\u20131264.","DOI":"10.1182\/blood-2005-03-1306"},{"key":"2019111703413905500_R7","doi-asserted-by":"crossref","unstructured":"Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213\u20132219.","DOI":"10.1182\/blood-2002-07-1960"},{"key":"2019111703413905500_R8","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Weenig RH, Pittlekow MR, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk & Lymph. 2005; 46: 703\u2013708.","DOI":"10.1080\/10428190500051380"},{"key":"2019111703413905500_R9","doi-asserted-by":"crossref","unstructured":"Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103:2091\u20132098.","DOI":"10.1002\/cncr.20999"},{"key":"2019111703413905500_R10","doi-asserted-by":"crossref","unstructured":"Tilly H, Lepage E, Coiffier B, et al. Intensive conventional (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284\u20134289.","DOI":"10.1182\/blood-2003-02-0542"},{"key":"2019111703413905500_R11","doi-asserted-by":"crossref","unstructured":"ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43:462\u2013469.","DOI":"10.1046\/j.1365-2559.2003.01726.x"},{"key":"2019111703413905500_R12","doi-asserted-by":"crossref","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20132479.","DOI":"10.1182\/blood-2003-09-3080"},{"key":"2019111703413905500_R13","doi-asserted-by":"crossref","unstructured":"Niitsu N, Okabe-Kado J, Okamoto M, et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood. 2001;97:1202\u20131210.","DOI":"10.1182\/blood.V97.5.1202"},{"key":"2019111703413905500_R14","doi-asserted-by":"crossref","unstructured":"Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005;29:1284\u20131293.","DOI":"10.1097\/01.pas.0000173238.17331.6b"},{"key":"2019111703413905500_R15","doi-asserted-by":"crossref","unstructured":"Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:1\u20138.","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"2019111703413905500_R16","doi-asserted-by":"crossref","unstructured":"Pescarmona E, Pignoloni P, Puopolo P, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001;195:361\u2013366.","DOI":"10.1002\/path.945"},{"key":"2019111703413905500_R17","doi-asserted-by":"crossref","unstructured":"Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494\u20135500.","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"2019111703413905500_R18","doi-asserted-by":"crossref","unstructured":"Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004;103:236\u2013241.","DOI":"10.1182\/blood-2002-05-1352"},{"key":"2019111703413905500_R19","doi-asserted-by":"crossref","unstructured":"Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004;10:4971\u20134982.","DOI":"10.1158\/1078-0432.CCR-04-0269"},{"key":"2019111703413905500_R20","doi-asserted-by":"crossref","unstructured":"Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560\u20131570.","DOI":"10.1038\/sj.onc.1209178"},{"key":"2019111703413905500_R21","unstructured":"Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype. Blood. 2000;96:2993\u20133000."},{"key":"2019111703413905500_R22","doi-asserted-by":"crossref","unstructured":"Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22:1682\u20131688.","DOI":"10.1200\/JCO.2004.10.172"},{"key":"2019111703413905500_R23","unstructured":"Advani R, Horwitz S, Harandi A, et al. Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine. [abstract]. Blood. 2003;102 (11):626."},{"key":"2019111703413905500_R24","doi-asserted-by":"crossref","unstructured":"Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK\/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41:1402\u20131408.","DOI":"10.1016\/j.ejca.2005.03.010"},{"key":"2019111703413905500_R25","doi-asserted-by":"crossref","unstructured":"Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: Clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795\u2013803.","DOI":"10.1200\/JCO.2000.18.4.795"},{"key":"2019111703413905500_R26","doi-asserted-by":"crossref","unstructured":"Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261\u20134269.","DOI":"10.1182\/blood-2003-05-1675"},{"key":"2019111703413905500_R27","doi-asserted-by":"crossref","unstructured":"Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12:2588\u20132593.","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"2019111703413905500_R28","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721\u20131726.","DOI":"10.1182\/blood.V98.6.1721"},{"key":"2019111703413905500_R29","doi-asserted-by":"crossref","unstructured":"Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy. Oncogene. 2005;24:6047\u20136057.","DOI":"10.1038\/sj.onc.1208979"},{"key":"2019111703413905500_R30","doi-asserted-by":"crossref","unstructured":"Besson C, Panelatti G, Delaunay C, et al. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with Antinucleosides, Alpha Interferon and Oral Etoposide. Leuk Lymph. 2002;43:2275\u20132279.","DOI":"10.1080\/1042819021000039983"},{"key":"2019111703413905500_R31","doi-asserted-by":"crossref","unstructured":"Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/ lymphoma. Leukemia. 2005;19:829\u2013834.","DOI":"10.1038\/sj.leu.2403682"},{"key":"2019111703413905500_R32","doi-asserted-by":"crossref","unstructured":"Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185\u2013187.","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"2019111703413905500_R33","doi-asserted-by":"crossref","unstructured":"Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Cancer. 2005;104:2437\u20132441.","DOI":"10.1002\/cncr.21449"},{"key":"2019111703413905500_R34","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Ravandi F. Purine analogues in advanced T-cell lymphoid malignancies. Elsevier. Semin Hematol. 2006;43(suppl 2):S27\u2013S34.","DOI":"10.1053\/j.seminhematol.2005.12.010"},{"key":"2019111703413905500_R35","doi-asserted-by":"crossref","unstructured":"Weidmann E, Hess G, Krause SW, et al. Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubin is an effective first-line regimen in peripheral T-cell lymphoma [abstract]. Blood. 2004;104 (11):2640a.","DOI":"10.1182\/blood.V104.11.2640.2640"},{"key":"2019111703413905500_R36","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636\u20134643.","DOI":"10.1182\/blood-2003-09-3068"},{"key":"2019111703413905500_R37","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Frye R, Turner M, et al. Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228. Proc ASCO. 2005;24:3061a.","DOI":"10.1200\/jco.2005.23.16_suppl.3061"},{"key":"2019111703413905500_R38","doi-asserted-by":"crossref","unstructured":"Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920\u20132924.","DOI":"10.1182\/blood-2003-10-3389"},{"key":"2019111703413905500_R39","doi-asserted-by":"crossref","unstructured":"Talpur R, Apisarnthanarax N, Ward S, et al. Treatment of refractory peripheral T-cell lymphoma with Denileukin Difitox (ONTAK\u00ae). Leuk Lymph. 2002;43:121\u2013126.","DOI":"10.1080\/10428190210183"},{"key":"2019111703413905500_R40","doi-asserted-by":"crossref","unstructured":"Hagberg H, Pettersson M, Bjerner T, et al. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol. 2005;22:191\u2013194.","DOI":"10.1385\/MO:22:2:191"},{"key":"2019111703413905500_R41","doi-asserted-by":"crossref","unstructured":"Cerveny CG, Law C-L, McCormick RS, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin\u2019s disease cells to conventional chemotherapeutics. Leukemia. 2005;19:1648\u20131655.","DOI":"10.1038\/sj.leu.2403884"},{"key":"2019111703413905500_R42","doi-asserted-by":"crossref","unstructured":"Mounier N, Gisselbrecht C, Briere J, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Group d\u2019Etude des Lymphomes de l\u2019 Adulte (GELA). Ann Oncol. 2004;15:1790\u20131797.","DOI":"10.1093\/annonc\/mdh471"},{"key":"2019111703413905500_R43","unstructured":"Majhail NS, Burns LJ. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Curr Hematol Rep. 2005;4:252\u2013259."},{"key":"2019111703413905500_R44","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high-dose chemotherapy and stem cell transplant. Leuk Lymph. 2004:45:2261\u20132267.","DOI":"10.1080\/10428190412331272749"},{"key":"2019111703413905500_R45","doi-asserted-by":"crossref","unstructured":"Zamkoff KW, Matulis MD, Mehta AC, et al. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant. 2004;33:635\u2013638.","DOI":"10.1038\/sj.bmt.1704392"},{"key":"2019111703413905500_R46","doi-asserted-by":"crossref","unstructured":"Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172\u20132176.","DOI":"10.1200\/JCO.2004.12.050"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/331\/1091657\/331_337ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/331\/1091657\/331_337ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T02:30:16Z","timestamp":1587263416000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/331\/19829\/Therapy-of-Peripheral-TNK-Neoplasms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.331","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}